FDA grants Priority Review to pertuzumab

FDA accepted and granted Priority Review to a BLA from Genentech Inc. for pertuzumab as a first-line treatment for HER2-positive metastatic breast cancer. The PDUFA date is June 8. Pertuzumab is a mAb...